The federal government is investing $50 million to help build the Critical Medicines Production Centre at the University of Alberta in Edmonton.

The non-repayable funding was announced by Eleanor Olszewski, minister of emergency management and community resilience and minister responsible for Prairies Economic Development Canada. Ottawa will deliver the investment through the Canadian Critical Drug Initiative (CCDI) under the Regional Innovation Ecosystems program.

The investment will support Applied Pharmaceutical Innovation (API), which is partnering with the university to advance construction of the facility. Once complete, the centre is expected to enable end-to-end, large-scale domestic manufacturing of a range of pharmaceutical products, helping reduce drug shortages, strengthen supply chains, and enhance Canada’s biodefence capabilities.

“In a more dangerous and uncertain world, Canada needs to build Canadian and buy Canadian — and that includes critical medicines,” said Olszewksi. “This new investment will support efforts to establish a major pharmaceutical manufacturing facility right here in Edmonton, strengthen Canada’s domestic supply chains, and support our sovereignty. It will also help grow Alberta’s world-class life sciences sector, drive cutting-edge innovation, and create good jobs in our province.”

The project is also expected to create more than 350 high-quality jobs, support at least 60 early-stage life sciences and biomanufacturing companies, and train 175 skilled workers, contributing to economic growth in the Edmonton region.

National Defence Minister David McGuinty said the federal investment will strengthen Canada’s ability to produce critical medicines domestically while advancing national security and supply- chain resilience.

“By supporting the Critical Medicines Production Centre, we are reinforcing biodefence capabilities for the Canadian Armed Forces and our NATO Allies and driving innovation in Canada’s life-sciences sector,” he said.

Andrew MacIsaac, CEO of API, said there has never been a more important time globally for resilient, sovereign critical-medicine supply capacity.

“We’re thankful for the ongoing support of PrairiesCan as we work to stand up Canada’s largest security of supply facility,” he said. “The work we do today will provide critical capacity for decades to come, enabling a made-in-Canada option for innovators and industry looking to commercialize as well as providing critical Canada-scale rapid resilience in times of crisis.”

The CCDI supports the production of critical medicines used in hospitals and pharmacies and is intended to bolster Canada’s domestic supply chains and preparedness in times of crisis, including for national defence.

Pictured: Future Critical Medicines Production Centre in Edmonton.

Rendering: API